Table 3.
Efficacy of UPA in U-ACHIEVE Maintenance Study
| Secondary Endpoints at Week 52*, N (%) | UPA 15 mg, N=47 | UPA 30 mg, N=58 | PBO, N=54 |
|---|---|---|---|
| Maintenance of clinical remission | 28 (59) | 40 (70) | 12 (22) |
| CS-free clinical remission | 27 (57) | 39 (68) | 12 (22) |
| Secondary endpoints at week 52*, N (%) | UPA 15 mg, N=148 | UPA 30 mg, N=154 | PBO, N=149 |
| Endoscopic improvement | 72 (49) | 95 (62) | 22 (15) |
| Endoscopic remission | 35 (24) | 40 (26) | 8 (5.6) |
| HEMI | 52 (35) | 75 (49) | 18 (12) |
| Secondary endpoints at week 52*, N (%) | UPA 15 mg, N=63 | UPA 30 mg, N=69 | PBO, N=74 |
| Maintenance of endoscopic improvement | 39 (62) | 48 (70) | 14 (19) |
| Secondary endpoints at week 52*, N (%) | UPA 15 mg, N=135 | UPA 30 mg, N=144 | PBO, N=134 |
| Maintenance of clinical response | 85 (63) | 111 (77) | 24 (18) |
Note: *P-value <0.001 PBO vs UPA15 mg or UPA30 mg.
Abbreviations: UPA, upadacitinib; PBO, placebo; HE, histologic endoscopic; MI, mucosal improvement.